Symphony Capital

Mark Schwartz, the firm's founder and Chairman, sets the overall investment strategy and has led the firm since 2002. Sundeep Arora serves as Managing Partner and is involved in day-to-day deal origination and underwriting. Investment committees follow a structured-credit discipline, evaluating each drug royalty deal on actuarial cash-flow projections rather than equity-style growth metrics.

Symphony does not take equity stakes in portfolio companies. The firm provides non-dilutive capital through loans or synthetic royalty purchases that entitle it to a percentage of a specific drug's revenue for a defined period or until a target return is achieved. Returns are driven by actual prescription volumes and reimbursement rates — not exit valuations or stock appreciation — which historically produces low correlation to the Nasdaq Biotechnology Index.

Symphony structures its own closed-end funds that make direct royalty and revenue-interest investments. The firm does not operate as a fund-of-funds and does not allocate capital to other healthcare managers. On large transactions, Symphony may offer co-investment opportunities alongside its main fund vehicle for select institutional limited partners.

The firm targets commercial-stage and near-approval biotechnology and pharmaceutical assets where regulatory risk has been substantially reduced. Symphony generally avoids pre-clinical and Phase 1 clinical-stage companies, focusing instead on drugs that are already approved by the FDA or EMA and generating revenue, or those in late Phase 3 trials with a clear path to market.

Symphony Capital is an independent asset management firm, not a family office. It raises capital from institutional investors — endowments, pensions, and fund-of-funds — across a series of closed-end private-credit vehicles. There is no single-family wealth backing the firm's balance sheet; Mark Schwartz and the partnership manage third-party institutional capital.

The firm avoids early-stage, pre-revenue biotechnology, as binary clinical-trial risk is incompatible with its cash-flow underwriting model. Symphony also does not invest in medical-device companies, healthcare IT, or healthcare services broadly defined — its mandate is deliberately narrow, confined to pharmaceutical and biologic drug royalty streams.

Symphony does not syndicate deals or participate in rounds led by external general partners. Because each transaction is a privately negotiated royalty or credit instrument tied to a specific drug's revenue stream, the firm controls its own origination and structuring in-house. Co-investment vehicles are limited to Symphony's own limited partners on select oversubscribed deals.